Attana biosensors provides a reliable, fast and versatile label-free method to study molecular interactions.
Accelerate to discover
Related topics
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
InAlyzer - The technology chosen by NASA
Jul 10, 2023
MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research
PET from Molecubes for imaging of neuroendocrine tumors
Jun 28, 2023
Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors:...
Jun 14, 2016
The team of Professor Dr. Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has recently published an article in PLOS ONE titled A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Professor Kontermann's group is working on the development of novel strategies for tumor therapy. The strategies are based on the use of specific ligands to target potent cytotoxic effector mechanism to the tumor. Their focus is on three effector arms: 1) bispecific antibodies for the retargeting of effector cells of the immune system (immunotherapy), 2) targeted carrier systems (liposomes, polymers) for drug delivery (chemotherapy), and 3) targeted cytotoxic fusion proteins (biotherapy). Main targets are molecules associated with the tumor vasculature (vascular targeting), since these structures are easily accessible for circulating agents and all solid tumors are dependent on vascularisation.
In this publication the group employed their Attana A200 system for affinity determination.
Brand profile
Attana biosensors provides a reliable, fast and versatile label-free method to study molecular interactions.
More info at:
www.attana.com/